A Phase 3 interventional study of iron isomaltoside 1000 (Monofer®) and iron sucrose (Venofer®) in Iron Deficiency Anaemia, sponsored by Pharmacosmos A/S. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-27.
Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 9 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.
Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 18 in phase 3, and was the 5th registered.
601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.
Browse Anemia, Iron-Deficiency studies →9 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:
Sichuan Huiyu Pharmaceutical Co., Ltd · Sites in China
Ages 18+
Hull University Teaching Hospitals NHS Trust · Sites in United Kingdom
Ages 18+
AHS Cancer Control Alberta · Sites in Canada
Ages 18+ · Women only
Children's Hospital Los Angeles · Sites in United States
Ages 16–60 · Women only · Healthy volunteers
Sun Yat-sen University · Sites in China
Ages 18–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 19 · Phase 4 7
First in 2007; this study’s year is marked. 1 started in 2014.
This study's enrollment of 511 is above the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 121 across the 32 interventional studies. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 32 have an industry lead sponsor. The 10 most frequent:
Pharmacosmos A/S is the lead sponsor of 36 studies on the registry; 5 are open to participants now.
15 studies in Anemia, Iron-Deficiency by Pharmacosmos A/S: none open now, none under way, none of them phase 3. Of 14 finished, 7 (50%) have results posted.
Among the 15 studies in Anemia, Iron-Deficiency by Pharmacosmos A/S, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2014, is one of 11 in phase 3, and was the 6th registered.
Pharmacosmos A/S’s Anemia, Iron-Deficiency studies by the year they started, since 2007.
3 of the studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05462704Phase 3Women and Infants Hospital of Rhode IslandIntravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy | 2027-03-30 |
| NCT06884280Phase 3Hull University Teaching Hospitals NHS TrustComparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study | 2027-10 |
| NCT04913649dr. P. NoordzijIntravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients | 2026-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, from their registry updates:
Among Pharmacosmos A/S’s 15 in Anemia, Iron-Deficiency:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the trial is to evaluate and compare the effect of iron isomaltoside 1000 to iron sucrose in its ability to increase haemoglobin (Hb) in subjects with IDA when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.
IDA is highly prevalent in subjects with gastrointestinal diseases and cancer, menstruating or pregnant women, and subjects who have undergone bariatric procedure. IDA can have a substantial medical and quality of life (QoL) burden on the subjects and the treatment of these subjects includes controlling the bleeding and replenishing lost iron. Oral iron administration is often used in the clinical practice at many clinics; however, oral iron may not be tolerated by all subjects. Hence, there is a need for an alternative iron treatment in subjects, who do not tolerate oral iron.
This study is planned to compare the efficacy and safety of iron isomaltoside 1000 with another parenteral iron preparation (iron sucrose) in subjects with IDA and who are intolerant or unresponsive to oral iron therapy or who need iron rapidly.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iron isomaltoside 1000 (Monofer®)
Drug: iron isomaltoside 1000 (Monofer®)
iron sucrose (Venofer®)
Drug: iron sucrose (Venofer®)
Number of Subjects With an Haemoglobin (Hb) Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 5
The primary efficacy endpoint of the trial was the count of subjects with an Hb increase of ≥ 2 g/dL from baseline at any time from week 1 to week 5. 'Any time' implied that if the endpoint was met at a time-point prior to or at week 5, the effect (increase of ≥ 2 g/dL) did not have to be maintained throughout the trial in order for a subject to be a responder. Number of responders (i.e. a subject with increase in Hb ≥ 2 g/dL from baseline at any time from week 1 to week 5) and percentages according to number of subjects in the analysis set were summarised.
Time frame: From baseline to week 5
Change in Hb Concentration
Time frame: From baseline to week 2, 4 and 5
Change in Serum (s)-Ferritin Concentration
Time frame: From baseline to week 1, 2, 4, and 5
Change in Transferrin Saturation (TSAT)
Time frame: From baseline to week 1, 2, 4, and 5
| Milestone | Iron Isomaltoside 1000 (Monofer®) | Iron Sucrose (Venofer®) |
|---|---|---|
| Started | 342 | 169 |
| Completed | 317 | 152 |
| Not completed | 25 | 17 |
The primary efficacy endpoint of the trial was the count of subjects with an Hb increase of ≥ 2 g/dL from baseline at any time from week 1 to week 5. 'Any time' implied that if the endpoint was met at a time-point prior to or at week 5, the effect (increase of ≥ 2 g/dL) did not have to be maintained throughout the trial in order for a subject to be a responder. Number of responders (i.e. a subject with increase in Hb ≥ 2 g/dL from baseline at any time from week 1 to week 5) and percentages according to number of subjects in the analysis set were summarised.
| participants | Iron Isomaltoside 1000 (Monofer®) | Iron Sucrose (Venofer®) |
|---|---|---|
| Number of Subjects With an Haemoglobin (Hb) Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 5 | 226 | 83 |
| g/dL | Iron Isomaltoside 1000 (Monofer®) | Iron Sucrose (Venofer®) |
|---|---|---|
| Week 2 | 1.56 ± 1.03 | 0.87 ± 0.90 |
| Week 4 | 2.35 ± 1.32 | 1.74 ± 1.17 |
| Week 5 | 2.52 ± 1.41 | 2.05 ± 1.27 |
| ng/mL | Iron Isomaltoside 1000 (Monofer®) | Iron Sucrose (Venofer®) |
|---|---|---|
| Week 1 | 431.2 ± 221.4 | 86.9 ± 84.8 |
| Week 2 | 516.6 ± 268.1 | 126.2 ± 87.2 |
| Week 4 | 285.3 ± 205.2 | 195.0 ± 126.2 |
| Week 5 | 241.2 ± 209.3 | 185.7 ± 166.8 |
| percent | Iron Isomaltoside 1000 (Monofer®) | Iron Sucrose (Venofer®) |
|---|---|---|
| Week 1 | 15.7 ± 9.6 | 3.3 ± 8.1 |
| Week 2 | 17.9 ± 9.8 | 5.7 ± 6.8 |
| Week 4 | 16.3 ± 9.0 | 11.5 ± 9.5 |
| Week 5 | 15.6 ± 8.6 | 11.8 ± 9.5 |
Collected over From screening until week 5. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Iron Isomaltoside 1000 (Monofer®) | 1/333 (0.3%) | 11/333 (3.3%) | 100/333 (30%) |
| Iron Sucrose (Venofer®) | 0/168 (0%) | 6/168 (3.6%) | 54/168 (32.1%) |
| Event | Iron Isomaltoside 1000 (Monofer®) | Iron Sucrose (Venofer®) |
|---|---|---|
| Vertigo positionalEar and labyrinth disorders | 0/333 | 1/168 |
| Stent malfunctionGeneral disorders | 0/333 | 1/168 |
| Anaphylactic reactionImmune system disorders | 0/333 | 1/168 |
| Postpartum haemorrhagePregnancy, puerperium and perinatal conditions | 0/333 | 1/168 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/333 | 1/168 |
| AnaemiaBlood and lymphatic system disorders | 0/333 | 1/168 |
| Cardiac failure congestiveCardiac disorders | 1/333 | 0/168 |
| Cardio-respiratory arrestCardiac disorders | 1/333 | 0/168 |
| DiarrhoeaGastrointestinal disorders | 1/333 | 0/168 |
| EnteritisGastrointestinal disorders | 1/333 | 0/168 |
| Event | Iron Isomaltoside 1000 (Monofer®) | Iron Sucrose (Venofer®) |
|---|---|---|
| HeadacheNervous system disorders | 18/333 | 11/168 |
| NauseaGastrointestinal disorders | 17/333 | 7/168 |
| RashSkin and subcutaneous tissue disorders | 14/333 | 1/168 |
| Upper respiratory tract infectionInfections and infestations | 4/333 | 6/168 |
| VomitingGastrointestinal disorders | 7/333 | 5/168 |
| DiarrhoeaGastrointestinal disorders | 3/333 | 5/168 |
| DysgeusiaNervous system disorders | 2/333 | 5/168 |
| FatiqueGeneral disorders | 4/333 | 5/168 |
| DizzinessNervous system disorders | 9/333 | 4/168 |
| Back painMusculoskeletal and connective tissue disorders | 8/333 | 2/168 |
FAS (N = 491): The FAS consisted of all subjects who were randomised, received at least one dose of the trial drug, and had at least one post-baseline Hb assessment.
| Age, Continuous(years) | Iron Isomaltoside 1000 (Monofer®) | Iron Sucrose (Venofer®) | Total |
|---|---|---|---|
| Mean | 49.3 ± 15.8 | 46.8 ± 14.9 | 48.4 ± 15.6 |
| Sex: Female, Male(Participants) | Iron Isomaltoside 1000 (Monofer®) | Iron Sucrose (Venofer®) | Total |
|---|---|---|---|
| Female | 309 | 154 | 463 |
| Male | 33 | 15 | 48 |
| Region of Enrollment(participants) | Iron Isomaltoside 1000 (Monofer®) | Iron Sucrose (Venofer®) | Total |
|---|---|---|---|
| United States | 342 | 169 | 511 |
The record gives a start of May 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2018, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron isomaltoside 1000